Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Gland Pharma Limited

Meeting Details

  • Type of Meeting: Postal Ballot through remote e-voting (no physical meeting)
  • Cut-off Date: October 01, 2026 (for determining shareholder eligibility)
  • Voting Period: October 07, 2026 (09:00 AM IST) to November 05, 2026 (05:00 PM IST)
  • Result Announcement: On or before November 09, 2026

Proposed Resolution

Item #1: Ordinary Resolution for Director Appointment

  • To appoint Mr. Xingli Wang (DIN: 11899926) as a Non-Executive & Non-Independent Director
  • He was initially appointed as an Additional Director effective October 01, 2026, under Section 161 of the Companies Act, 2013
  • The appointment requires shareholder approval within three months as per Regulation 17(1C) of SEBI LODR
  • Mr. Wang possesses expertise in R&D, Operations, Quality, and global clinical trials

Voting Process and Methods

  • Voting Method: Remote e-voting only (no physical voting)
  • Service Provider: MUFG Intime India Private Limited (formerly Link Intime India Private Limited)
  • Voting Platform: InstaVote (https://instavote.linkintime.co.in)
  • Event Number (EVEN): 260921
  • Voting Rights: Proportional to shares held as of October 01, 2026 cut-off date
  • Once cast, votes cannot be changed

Shareholder Communication

  • Notice sent only electronically to members whose email addresses are registered as of October 01, 2026
  • No physical copies of notice, ballot forms, or business reply envelopes sent
  • Notice available on company website (glandpharma.com), stock exchange websites (BSE, NSE), and MUFG Intime's platform

Scrutinizer Appointment

  • Ms. D. Soumya, Practicing Company Secretary (Membership No. F11754, CP No. 13199) appointed as Scrutinizer
  • She will scrutinize votes and submit report to the Chairman
  • Her decision on vote validity is final

Compliance Statements

  • Compliance with Sections 108, 110 of Companies Act, 2013
  • Compliance with Companies (Management and Administration) Rules, 2014
  • Compliance with SEBI LODR Regulations, 2015 (particularly Regulation 44)
  • Compliance with multiple MCA Circulars (14/2020, 17/2020, 22/2020, 33/2020, 39/2020, 02/2021, 10/2021, 20/2021, 3/2022, 11/2022, 09/2023, 09/2024, 03/2025)
  • Compliance with SEBI Circulars dated December 9, 2020; July 11, 2023; and November 11, 2024
  • Compliance with Secretarial Standard on General Meetings (SS-2)

Director Details

Mr. Xingli Wang (DIN: 11899926)

  • Age: 63 years (Date of Birth: December 08, 1962)
  • Qualification: Bachelor's degree in Medicine from Shandong Medical College; Doctorate in Cardiovascular Science from University of New South Wales
  • Experience: President of Fosun Pharma; CEO of Global R&D Center and innovative medicine division at Fosun Pharma; Former roles at Novartis AG, Schering Plough, and academic positions
  • Current Directorships: Non-Executive Director of Shanghai Henlius (HKEX: 02696)
  • Shareholding: Nil shares in Gland Pharma as of October 01, 2026
  • Not related to any other directors or key managerial personnel
  • Terms of appointment: Available for inspection in electronic mode during business hours until November 5, 2026

Additional Information

  • Contact: +91 84556 99999; investors@glandpharma.com
  • Helpdesk contacts provided for voting assistance: MUFG Intime (022-49186000), NSDL (022-48867000), CDSL (1800225533)